| DC7804 |
Anacetrapib(MK0859)
Featured
|
Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3. |
|
| DC9861 |
BMS-779788(XL-652)
Featured
|
BMS-779788(XL652) is a novel small-molecule modulator of the Liver X Receptor (LXR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. |
|
| DC7397 |
Darapladib
Featured
|
Darapladib is a selective and orally active inhibitor of Lp-PLA2 (IC50= 270 pM) |
|
| DC2072 |
LXR623
Featured
|
LXR-623 is a novel Liver X Receptor modulator |
|
| DC9456 |
MK-0354 |
MK-0354 is a partial agonist of GPR109a receptor, for hGPR109a/ mGPR109a with EC50 of 1.65/1.08 μM, showed no activation of GPR109b.
|
|
| DC9609 |
Terutroban
Featured
|
Terutroban is a thromboxane/prostaglandin endoperoxide receptor antagonist.
|
|
| DC7519 |
Torcetrapib
Featured
|
Torcetrapib is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3. |
|
